DEXORGEN INC.

DEXORGEN INC. specializes in advanced biotechnological research and laboratory services focused on neurodevelopmental disorders and infectious disease therapeutics. The company conducts cutting-edge work in induced pluripotent stem cell (iPSC) derivation and characterization, particularly for brain organoid models of X-linked mental retardation syndromes, and delivers high-complexity protein production services for viral envelope antigens such as HTLV envelope proteins. Their technical expertise spans cellular reprogramming, 3D tissue modeling, molecular characterization, and small-molecule drug discovery, with demonstrated proficiency in developing novel PDE4B inhibitors for alcohol use disorder under SBIR Phase II frameworks. DEXORGEN’s differentiation lies in its ability to bridge complex cellular phenotyping with translational pharmacology, enabling preclinical validation of therapeutic candidates for rare neurological and virological conditions. The contractor maintains a consistent relationship with the Department of Health and Human Services, delivering specialized research and testing services across multiple divisions including NIH and CDC-aligned programs. Their engagements typically involve mechanistic studies of neurodevelopmental pathologies, antigen production for diagnostic and vaccine platforms, and early-stage drug development under federal SBIR initiatives, indicating a trusted role in supporting HHS’s biomedical innovation pipeline. DEXORGEN’s primary industry focus is in testing laboratories and services (NAICS 541380) and biotechnology research and development (NAICS 541714), positioning them as a niche provider of translational neuroscience and virology solutions. They serve the federal biomedical research market by offering specialized in vitro models and analytical services not widely available through conventional contract research organizations. As a small business structured as a 2L entity based in Rockville, Maryland, DEXORGEN operates with agility in high-compliance federal research environments. While currently holding no formal government certifications, its geographic proximity to federal research hubs and demonstrated execution on complex HHS-funded projects underscore its strategic alignment with the national biodefense and neurological health agenda.